Market Pathways covers the people, challenges, and opportunities impacting the global medtech regulatory, reimbursement, and policy communities. We invite you to explore our coverage. Think Strategically.
Subscribe Today
Dr. Oz signals support for more automatic Medicare coverage of medtech; FDA staffers face space and other challenges in their return to in-person work; China NMPA advances policies for domestic manufacturing and clinical trial oversight; MedTech Europe’s regulatory advocacy; and more.
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Diagnostic Emergency Use Authorizations in March 2025. Updated March 18, 2025.
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Diagnostic Emergency Use Authorizations in March 2025. Updated March 18, 2025.